Comparing silver plans with cost-sharing reductions
Elena, 58, earns $33,000, about 175% of the federal poverty level for a single adult. She needs a silver plan. She takes four brand-name drugs monthly and sees a rheumatologist every eight weeks. She compares two silver plans: Plan A has a $5,000 deductible, $50 primary-care copay, $90 specialist copay, a separate $500 drug deductible, and covers two of her four drugs. Plan B has a $4,000 deductible, $30 primary-care copay, $60 specialist copay, no drug deductible, and covers all four drugs, but its specialist network excludes her rheumatologist and it has no out-of-network benefits. Plan A premium is $480; Plan B is $520; the benchmark silver premium is $500. She asks why the plans look different when both are silver and whether she can get extra help with copays.
1. Explain Elena’s cost-sharing reduction eligibility and how CSRs change the cost-sharing structure of a silver plan.
Read the worked answer
At about 175% of the federal poverty level, Elena is in a CSR-eligible income range if she is otherwise eligible and enrolls in a silver plan. CSRs are not a separate plan; they are a version of a silver plan with a higher actuarial value. The insurer lowers the deductible, copays, and out-of-pocket maximum compared with the standard silver plan.
CSRs are available only on silver plans. Bronze and gold plans do not have CSR variants, so Elena should compare silver plans specifically. Both Plan A and Plan B are silver, but she must confirm that each insurer offers a CSR variant at her income level and check the actual reduced cost-sharing schedule, not just the standard deductible shown in advertising. The premium tax credit is calculated separately and can be applied to any metal level, but the CSR benefit depends on selecting silver.
2. Compare Plan A and Plan B beyond the monthly premium, including expected annual costs and drug coverage.
Read the worked answer
The premium comparison alone is misleading. Plan A costs $480 per month, which is $20 below the $500 benchmark, while Plan B costs $520, which is $20 above the benchmark. With APTC, Elena’s premium contribution is based on the benchmark, so Plan B may require her to pay the $20 difference, while Plan A may reduce her premium below the benchmark amount.
However, Plan A has a higher deductible, higher copays, a separate drug deductible, and covers only two of her four drugs. Plan B has a lower deductible, lower copays, no drug deductible, and covers all four drugs. Elena should add the annual premium to expected cost sharing for her drugs and rheumatology visits. If Plan A does not cover two drugs, she could face full retail cost or need an exception, which may erase the premium savings. She should use the Summary of Benefits and Coverage and the formulary to estimate annual costs, and confirm the CSR version’s actual deductible and copays before deciding.
3. What network and formulary steps should Elena take before enrolling, and how should the agent handle the rheumatologist being out of network in Plan B?
Read the worked answer
Elena should verify that her rheumatologist is in each plan’s network, that any needed referral is permitted, and that her four drugs are on the formulary at a manageable tier. She should also check whether prior authorization or step therapy applies and whether the plan has a transition-of-care policy. The agent should not rely on a general provider directory alone; a call to the plan and to the physician’s office can confirm network status.
Plan B’s exclusion of her rheumatologist is a major issue because the plan has no out-of-network benefits. Unless she is willing to change specialists and confirm a new in-network rheumatologist, Plan B may leave her paying the full cost of those visits. For Plan A, the missing drugs should prompt a formulary exception request or a check for covered alternatives before enrollment. The agent should document the findings and avoid promising that an exception will be granted.